Thematic review series: High density lipoprotein structure, function, and metabolism: Unraveling the complexities of the HDL lipidome

Journal of Lipid Research

Volumn 54, Issue 11, 2013, Pages 2950-2963

  Kontush, Anatol ^a   Lhomme, Marie ^b   Chapman, M John ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

Author keywords

HDL dysfunction; HDL function; Lipidomics; Phospholipids; Sphingolipids

Indexed keywords

CARDIOLIPIN; CERAMIDE; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; LIPIDOME; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PHOSPHOLIPID; PLASMALOGEN; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; STEROID; STEROL DERIVATIVE; TRIACYLGLYCEROL;

BIOLOGICAL ACTIVITY; CELL PROTECTION; CELL TRANSPORT; CHOLESTEROL TRANSPORT; HUMAN; LIPID ANALYSIS; LIPID COMPOSITION; LIPIDOMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; VASODILATATION; ANIMAL; CHEMISTRY; CLASSIFICATION; DISEASES; HDL DYSFUNCTION; HDL FUNCTION; METABOLISM;

HDL DYSFUNCTION; HDL FUNCTION; LIPIDOMICS; PHOSPHOLIPIDS; SPHINGOLIPIDS;

ANIMALS; DISEASE; HUMANS; LIPOPROTEINS, HDL;

EID: 84886022765     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R036095     Document Type: Review

References (146)

1. Kontush, A., and M. J. Chapman. 2010. Lipidomics as a tool for the study of lipoprotein metabolism. Curr. Atheroscler. Rep. 12: 194-201.
2. Scherer, M., A. Bottcher, and G. Liebisch. 2011. Lipid profiling of lipoproteins by electrospray ionization tandem mass spectrometry. Biochim. Biophys. Acta. 1811: 918-924.
3. Kontush, A., and M. J. Chapman. 2012. High-Density Lipoproteins: Structure, Metabolism, Function and Therapeutics. Wiley & Sons, New York.
4. Wiesner, P., K. Leidl, A. Boettcher, G. Schmitz, and G. Liebisch. 2009. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J. Lipid Res. 50: 574-585.
5. Yetukuri, L., S. Soderlund, A. Koivuniemi, T. Seppanen-Laakso, P. S. Niemela, M. Hyvonen, M-R. Taskinen, I. Vattulainen, M. Jauhiainen, and M. Oresic. 2010. Composition and lipid spatial distribution of HDL particles in subjects with low and high HDLcholesterol. J. Lipid Res. 51: 2341-2351.
6. Quehenberger, O., A. M. Armando, A. H. Brown, S. B. Milne, D. S. Myers, A. H. Merrill, S. Bandyopadhyay, K. N. Jones, S. Kelly, R. L. Shaner, et al. 2010. Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 51: 3299-3305.
7. Kontush, A., P. Therond, A. Zerrad, M. Couturier, A. Negre-Salvayre, J. A. de Souza, S. Chantepie, and M. J. Chapman. 2007. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol. 27: 1843-1849. (Pubitemid 47207181)
8. Scherer, M., A. Bottcher, G. Schmitz, and G. Liebisch. 2011. Sphingolipid profiling of human plasma and FPLC-separated lipoprotein fractions by hydrophilic interaction chromatography tandem mass spectrometry. Biochim. Biophys. Acta. 1811: 68-75.
9. Lee, J. Y., H. K. Min, D. Choi, and M. H. Moon. 2010. Profiling of phospholipids in lipoproteins by multiplexed hollow fiber flow field-flow fractionation and nanoflow liquid chromatographytandem mass spectrometry. J. Chromatogr. A. 1217: 1660-1666.
10. Deguchi, H., J. A. Fernandez, T. M. Hackeng, C. L. Banka, and J. H. Griffin. 2000. Cardiolipin is a normal component of human plasma lipoproteins. Proc. Natl. Acad. Sci. USA. 97: 1743-1748. (Pubitemid 30118513)
11. Stahlman, M., H. T. Pham, M. Adiels, T. W. Mitchell, S. J. Blanksby, B. Fagerberg, K. Ekroos, and J. Boren. 2012. Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes. Diabetologia. 55: 1156-1166.
12. Hidaka, H., K. Yamauchi, H. Ohta, T. Akamatsu, T. Honda, and T. Katsuyama. 2008. Specific, rapid, and sensitive enzymatic measurement of sphingomyelin, phosphatidylcholine and lysophosphatidylcholine in serum and lipid extracts. Clin. Biochem. 41: 1211-1217.
13. Pruzanski, W., E. Stefanski, F. C. de Beer, M. C. de Beer, A. Ravandi, and A. Kuksis. 2000. Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J. Lipid Res. 41: 1035-1047. (Pubitemid 30483006)
14. Subbaiah, P. V., and M. Liu. 1996. Disparate effects of oxidation on plasma acyltransferase activities: inhibition of cholesterol esterifi cation but stimulation of transesterification of oxidized phospholipids. Biochim. Biophys. Acta. 1301: 115-126. (Pubitemid 26193069)
15. Maeba, R., and N. Ueta. 2003. Ethanolamine plasmalogen and cholesterol reduce the total membrane oxidizability measured by the oxygen uptake method. Biochem. Biophys. Res. Commun. 302: 265-270. (Pubitemid 36397915)
16. Maeba, R., and N. Ueta. 2003. Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers. J. Lipid Res. 44: 164-171. (Pubitemid 36114782)
17. Maeba, R., Y. Sawada, H. Shimasaki, I. Takahashi, and N. Ueta. 2002. Ethanolamine plasmalogens protect cholesterol-rich liposomal membranes from oxidation caused by free radicals. Chem. Phys. Lipids. 120: 145-151. (Pubitemid 35333407)
18. Davidson, W. S., D. L. Sparks, S. Lund-Katz, and M. C. Phillips. 1994. The molecular basis for the difference in charge between pre-beta- and alpha-migrating high density lipoproteins. J. Biol. Chem. 269: 8959-8965.
19. Boucher, J. G., T. Nguyen, and D. L. Sparks. 2007. Lipoprotein electrostatic properties regulate hepatic lipase association and activity. Biochem. Cell Biol. 85: 696-708. (Pubitemid 351198417)
20. Morrow, J. D. 2005. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 25: 279-286. (Pubitemid 40189146)
21. Proudfoot, J. M., A. E. Barden, W. M. Loke, K. D. Croft, I. B. Puddey, and T. A. Mori. 2009. HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J. Lipid Res. 50: 716-722.
22. Rye, K. A., N. J. Hime, and P. J. Barter. 1996. The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins. J. Biol. Chem. 271: 4243-4250.
23. Saito, H., I. Arimoto, M. Tanaka, T. Sasaki, T. Tanimoto, S. Okada, and T. Handa. 2000. Inhibition of lipoprotein lipase activity by sphingomyelin: role of membrane surface structure. Biochim. Biophys. Acta. 1486: 312-320. (Pubitemid 30618871)
24. Nilsson, A., and R. D. Duan. 2006. Absorption and lipoprotein transport of sphingomyelin. J. Lipid Res. 47: 154-171. (Pubitemid 43107459)
25. Lucke, S., and B. Levkau. 2010. Endothelial functions of sphingosine-1-phosphate. Cell. Physiol. Biochem. 26: 87-96.
26. de Souza, J. A., C. Vindis, A. Negre-Salvayre, K. A. Rye, M. Couturier, P. Therond, S. Chantepie, R. Salvayre, M. J. Chapman, and A. Kontush. 2010. Small, dense HDL3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J. Cell. Mol. Med. 14: 608-620.
27. de Souza, J. A., C. Vindis, B. Hansel, A. Negre-Salvayre, P. Therond, C. V. Serrano, Jr., S. Chantepie, R. Salvayre, E. Bruckert, M. J. Chapman, et al. 2008. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis. 197: 84 -94. (Pubitemid 351273276)
28. Pappu, R., S. R. Schwab, I. Cornelissen, J. P. Pereira, J. B. Regard, Y. Xu, E. Camerer, Y. W. Zheng, Y. Huang, J. G. Cyster, et al. 2007. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 316: 295-298. (Pubitemid 46633109)
29. Yatomi, Y., F. Ruan, S. Hakomori, and Y. Igarashi. 1995. Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood. 86: 193-202.
30. Nofer, J-R., and G. Assmann. 2005. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc. Med. 15: 265-271. (Pubitemid 41437910)
31. Dawson, G., A. W. Kruski, and A. M. Scanu. 1976. Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J. Lipid Res. 17: 125-131.
32. Senn, H. J., M. Orth, E. Fitzke, H. Wieland, and W. Gerok. 1989. Gangliosides in normal human serum. Concentration, pattern and transport by lipoproteins. Eur. J. Biochem. 181: 657-662. (Pubitemid 19146930)
33. Kivatinitz, S. C., P. Favini, and R. Ghidoni. 1992. Gangliosides released by the perfused rat liver are associated to high density lipoprotein. Biochem. Int. 26: 821-829.
34. Valentino, L. A., and S. Ladisch. 1992. Localization of shed human tumor gangliosides: association with serum lipoproteins. Cancer Res. 52: 810-814.
35. Senn, H. J., M. Orth, E. Fitzke, W. Koster, H. Wieland, and W. Gerok. 1992. Human serum gangliosides in hypercholesterolemia, before and after extracorporeal elimination of LDL. Atherosclerosis. 94: 109-117.
36. Burkard, I., A. von Eckardstein, G. Waeber, P. Vollenweider, and K. M. Rentsch. 2007. Lipoprotein distribution and biological variation of 24S- and 27-hydroxycholesterol in healthy volunteers. Atherosclerosis. 194: 71-78. (Pubitemid 47464309)
37. Tikkanen, M. J., V. Vihma, M. Jauhiainen, A. Hockerstedt, H. Helisten, and M. Kaamanen. 2002. Lipoprotein-associated estrogens. Cardiovasc. Res. 56: 184-188. (Pubitemid 35223488)
38. Skipski, V. P., M. Barclay, R. K. Barclay, V. A. Fetzer, J. J. Good, and F. M. Archibald. 1967. Lipid composition of human serum lipoproteins. Biochem. J. 104: 340-352.
39. Lalanne, F., V. Pruneta, S. Bernard, and G. Ponsin. 1999. Distribution of diacylglycerols among plasma lipoproteins in control subjects and in patients with non-insulin-dependent diabetes. Eur. J. Clin. Invest. 29: 139-144. (Pubitemid 29090252)
40. Bowry, V. W., K. K. Stanley, and R. Stocker. 1992. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl. Acad. Sci. USA. 89: 10316-10320.
41. Garner, B., P. K. Witting, A. R. Waldeck, J. K. Christison, M. Raftery, and R. Stocker. 1998. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J. Biol. Chem. 273: 6080-6087. (Pubitemid 28144687)
42. Goulinet, S., and M. J. Chapman. 1997. Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17: 786-796. (Pubitemid 27169143)
43. Rosenson, R. S., H. B. Brewer, Jr., M. J. Chapman, S. Fazio, M. M. Hussain, A. Kontush, R. M. Krauss, J. D. Otvos, A. T. Remaley, and E. J. Schaefer. 2011. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 57: 392-410.
44. Duong, P. T., H. L. Collins, M. Nickel, S. Lund-Katz, G. H. Rothblat, and M. C. Phillips. 2006. Characterization of nascent HDL particles and microparticles formed by ABCA1-mediated effl ux of cellular lipids to apoA-I. J. Lipid Res. 47: 832-843.
45. Christoffersen, C., H. Obinata, S. B. Kumaraswamy, S. Galvani, J. Ahnstrom, M. Sevvana, C. Egerer-Sieber, Y. A. Muller, T. Hla, L. B. Nielsen, et al. 2011. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc. Natl. Acad. Sci. USA. 108: 9613-9618.
46. Davidson, W. S., R. A. G. D. Silva, S. Chantepie, W. R. Lagor, M. J. Chapman, and A. Kontush. 2009. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 29: 870-876.
47. Karuna, R., A. G. Holleboom, M. M. Motazacker, J. A. Kuivenhoven, R. Frikke-Schmidt, A. Tybjaerg-Hansen, S. Georgopoulos, M. van Eck, T. J. van Berkel, A. von Eckardstein, et al. 2011. Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. Atherosclerosis. 214: 448-455.
48. Nakamura, Y., L. Kotite, Y. Gan, T. A. Spencer, C. J. Fielding, and P. E. Fielding. 2004. Molecular mechanism of reverse cholesterol transport: reaction of pre-beta-migrating high-density lipoprotein with plasma lecithin/cholesterol acyltransferase. Biochemistry. 43: 14811-14820. (Pubitemid 39524956)
49. Subbaiah, P. V., and M. Liu. 1993. Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction. J. Biol. Chem. 268: 20156-20163. (Pubitemid 23278915)
50. Bolin, D. J., and A. Jonas. 1996. Sphingomyelin inhibits the lecithincholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J. Biol. Chem. 271: 19152-19158. (Pubitemid 26271578)
51. Yancey, P. G., M. de la Llera-Moya, S. Swarnakar, P. Monzo, S. M. Klein, M. A. Connelly, W. J. Johnson, D. L. Williams, and G. H. Rothblat. 2000. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J. Biol. Chem. 275: 36596-36604. (Pubitemid 32002059)
52. Davidson, W. S., K. L. Gillotte, S. Lund-Katz, W. J. Johnson, G. H. Rothblat, and M. C. Phillips. 1995. The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol. J. Biol. Chem. 270: 5882-5890.
53. Litman, B. J., E. N. Lewis, and I. W. Levin. 1991. Packing characteristics of highly unsaturated bilayer lipids: Raman spectroscopic studies of multilamellar phosphatidylcholine dispersions. Biochemistry. 30: 313-319.
54. Guha, M., X. Gao, S. Jayaraman, and O. Gursky. 2008. Correlation of structural stability with functional remodeling of high-density lipoproteins: the importance of being disordered. Biochemistry. 47: 11393-11397.
55. Guha, M., D. L. Gantz, and O. Gursky. 2008. Effects of acyl chain length, unsaturation, and pH on thermal stability of model discoidal HDLs. J. Lipid Res. 49: 1752-1761.
56. Marmillot, P., S. Patel, and M. R. Lakshman. 2007. Reverse cholesterol transport is regulated by varying fatty acyl chain saturation and sphingomyelin content in reconstituted high-density lipoproteins. Metabolism. 56: 251-259. (Pubitemid 46074073)
57. Ma, C. I., J. A. Beckstead, A. Thompson, A. Hafiane, R. H. Wang, R. O. Ryan, and R. S. Kiss. 2012. Tweaking the cholesterol efflux capacity of reconstituted HDL. Biochem. Cell Biol. 90: 636-645.
58. Zerrad-Saadi, A., P. Therond, S. Chantepie, M. Couturier, K-A. Rye, M. J. Chapman, and A. Kontush. 2009. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 29: 2169-2175.
59. Vila, A., W. Korytowski, and A. W. Girotti. 2002. Spontaneous transfer of phospholipid and cholesterol hydroperoxides between cell membranes and low-density lipoprotein: assessment of reaction kinetics and prooxidant effects. Biochemistry. 41: 13705-13716. (Pubitemid 35332708)
60. Sparks, D. L., W. S. Davidson, S. Lund-Katz, and M. C. Phillips. 1995. Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability. J. Biol. Chem. 270: 26910-26917.
61. Curtiss, L. K., D. J. Bonnet, and K. A. Rye. 2000. The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study. Biochemistry. 39: 5712-5721. (Pubitemid 30307959)
62. Braschi, S., T. A. Neville, M. C. Vohl, and D. L. Sparks. 1999. Apolipoprotein A-I charge and conformation regulate the clearance of reconstituted high density lipoprotein in vivo. J. Lipid Res. 40: 522-532. (Pubitemid 29116156)
63. Baker, P. W., K. A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter. 1999. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J. Lipid Res. 40: 345-353. (Pubitemid 29069810)
64. Xia, P., M. A. Vadas, K. A. Rye, P. J. Barter, and J. R. Gamble. 1999. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem. 274: 33143-33147. (Pubitemid 129535357)
65. Perrin-Cocon, L., O. Diaz, M. Carreras, S. Dollet, A. Guironnet-Paquet, P. Andre, and V. Lotteau. 2012. High-density lipoprotein phospholipids interfere with dendritic cell Th1 functional maturation. Immunobiology. 217: 91-99.
66. Baker, P. W., K. A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter. 2000. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J. Lipid Res. 41: 1261-1267. (Pubitemid 30666892)
67. Tolle, M., A. Pawlak, M. Schuchardt, A. Kawamura, U. J. Tietge, S. Lorkowski, P. Keul, G. Assmann, J. Chun, B. Levkau, et al. 2008. HDL-associated lysosphingolipids inhibit NAD(P)H oxidasedependent monocyte chemoattractant protein-1 production. Arterioscler. Thromb. Vasc. Biol. 28: 1542-1548.
68. Keul, P., S. Lucke, K. von Wnuck Lipinski, C. Bode, M. Graler, G. Heusch, and B. Levkau. 2011. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ. Res. 108: 314-323.
69. Kimura, T., K. Sato, A. Kuwabara, H. Tomura, M. Ishiwara, I. Kobayashi, M. Ui, and F. Okajima. 2001. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 276: 31780-31785.
70. Okajima, F. 2002. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim. Biophys. Acta. 1582: 132-137. (Pubitemid 34634121)
71. Kimura, T., K. Sato, E. Malchinkhuu, H. Tomura, K. Tamama, A. Kuwabara, M. Murakami, and F. Okajima. 2003. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 23: 1283-1288. (Pubitemid 36871285)
72. Zhang, B., H. Tomura, A. Kuwabara, T. Kimura, S-i. Miura, K. Noda, F. Okajima, and K. Saku. 2005. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis. 178: 199-205. (Pubitemid 39600834)
73. Kwon, Y. G., J. K. Min, K. M. Kim, D. J. Lee, T. R. Billiar, and Y. M. Kim. 2001. Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production. J. Biol. Chem. 276: 10627-10633. (Pubitemid 38089231)
74. Tao, R., H. E. Hoover, N. Honbo, M. Kalinowski, C. C. Alano, J. S. Karliner, and R. Raffai. 2010. High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am. J. Physiol. Heart Circ. Physiol. 298: H1022-H1028.
75. Frias, M. A., U. Lang, C. Gerber-Wicht, and R. W. James. 2010. Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. Cardiovasc. Res. 85: 118-126.
76. Frias, M. A., R. W. James, C. Gerber-Wicht, and U. Lang. 2009. Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of sphingosine-1-phosphate. Cardiovasc. Res. 82: 313-323.
77. Tamama, K., H. Tomura, K. Sato, E. Malchinkhuu, A. Damirin, T. Kimura, A. Kuwabara, M. Murakami, and F. Okajima. 2005. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis. 178: 19-23. (Pubitemid 39600811)
78. Herzog, C., M. Schmitz, B. Levkau, I. Herrgott, J. Mersmann, J. Larmann, K. Johanning, M. Winterhalter, J. Chun, F. U. Muller, et al. 2010. Intravenous sphingosylphosphorylcholine protects ischemic and postischemic myocardial tissue in a mouse model of myocardial ischemia/reperfusion injury. Mediators Inflamm. 2010: 425191.
79. Nofer, J. R., M. Fobker, G. Hobbel, R. Voss, I. Wolinska, M. Tepel, W. Zidek, R. Junker, U. Seedorf, A. von Eckardstein, et al. 2000. Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysosphingolipid. Involvement in mitogenesis but not in cholesterol efflux. Biochemistry. 39: 15199-15207.
80. Bricarello, D. A., E. J. Mills, J. Petrlova, J. C. Voss, and A. N. Parikh. 2010. Ganglioside embedded in reconstituted lipoprotein binds cholera toxin with elevated affinity. J. Lipid Res. 51: 2731-2738.
81. Mineo, C., H. Deguchi, J. H. Griffin, and P. W. Shaul. 2006. Endothelial and antithrombotic actions of HDL. Circ. Res. 98: 1352-1364. (Pubitemid 43948059)
82. Nofer, J. R., M. van der Giet, M. Tolle, I. Wolinska, K. von Wnuck Lipinski, H. A. Baba, U. J. Tietge, A. Godecke, I. Ishii, B. Kleuser, et al. 2004. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113: 569-581. (Pubitemid 38542506)
83. Igarashi, J., and T. Michel. 2008. S1P and eNOS regulation. Biochim. Biophys. Acta. 1781: 489-495.
84. Matsuo, Y., S. Miura, A. Kawamura, Y. Uehara, K. A. Rye, and K. Saku. 2007. Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation. Atherosclerosis. 194: 159-168. (Pubitemid 47464317)
85. Gonzalez-Diez, M., C. Rodriguez, L. Badimon, and J. Martinez-Gonzalez. 2008. Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin. Thromb. Haemost. 100: 119-126. (Pubitemid 351948753)
86. Gong, M., M. Wilson, T. Kelly, W. Su, J. Dressman, J. Kincer, S. V. Matveev, L. Guo, T. Guerin, X. A. Li, et al. 2003. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J. Clin. Invest. 111: 1579-1587. (Pubitemid 38063291)
87. Badeau, R. M., J. Metso, K. Wahala, M. J. Tikkanen, and M. Jauhiainen. 2009. Human macrophage cholesterol efflux potential is enhanced by HDL-associated 17beta-estradiol fatty acyl esters. J. Steroid Biochem. Mol. Biol. 116: 44-49.
88. Paatela, H., E. Mervaala, S. Deb, K. Wahala, and M. J. Tikkanen. 2009. HDL-associated dehydroepiandrosterone fatty acyl esters: enhancement of vasodilatory effect of HDL. Steroids. 74: 814-818.
89. Brodde, M. F., S. J. Korporaal, G. Herminghaus, M. Fobker, T. J. Van Berkel, U. J. Tietge, H. Robenek, M. Van Eck, B. E. Kehrel, and J. R. Nofer. 2011. Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI: role of negatively charged phospholipids. Atherosclerosis. 215: 374-382.
90. Ozerova, I. N., N. V. Perova, N. V. Shchel'tsyna, and M. N. Mamedov. 2007. Parameters of high-density lipoproteins in patients with arterial hypertension in combination with other components of metabolic syndrome. Bull. Exp. Biol. Med. 143: 320-322. (Pubitemid 47323247)
91. Holzer, M., R. Birner-Gruenberger, T. Stojakovic, D. El-Gamal, V. Binder, C. Wadsack, A. Heinemann, and G. Marsche. 2011. Uremia alters HDL composition and function. J. Am. Soc. Nephrol. 22: 1631-1641.
92. Holzer, M., P. Wolf, S. Curcic, R. Birner-Gruenberger, W. Weger, M. Inzinger, D. El-Gamal, C. Wadsack, A. Heinemann, and G. Marsche. 2012. Psoriasis alters HDL composition and cholesterol efflux capacity. J. Lipid Res. 53: 1618-1624.
93. Papathanasiou, A., C. Kostara, M. T. Cung, K. Seferiadis, M. Elisaf, E. Bairaktari, and I. A. Goudevenos. 2008. Analysis of the composition of plasma lipoproteins in patients with extensive coronary heart disease using 1H NMR spectroscopy. Hellenic J. Cardiol. 49: 72-78. (Pubitemid 351631141)
94. Khovidhunkit, W., M. S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196. (Pubitemid 38802622)
95. Clifton, P. M., A. M. Mackinnon, and P. J. Barter. 1985. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J. Lipid Res. 26: 1389-1398. (Pubitemid 16189736)
96. Cabana, V. G., J. N. Siegel, and S. M. Sabesin. 1989. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J. Lipid Res. 30: 39-49. (Pubitemid 19037564)
97. Crowl, R. M., T. J. Stoller, R. R. Conroy, and C. R. Stoner. 1991. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J. Biol. Chem. 266: 2647-2651. (Pubitemid 21909111)
98. Pruzanski, W., P. Vadas, and J. Browning. 1993. Secretory nonpancreatic group II phospholipase A2: role in physiologic and inflammatory processes. J. Lipid Mediat. 8: 161-167. (Pubitemid 23297961)
99. Tietge, U. J., C. Maugeais, S. Lund-Katz, D. Grass, F. C. de Beer, and D. J. Rader. 2002. Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler. Thromb. Vasc. Biol. 22: 1213-1218. (Pubitemid 34764876)
100. Lee, C. Y., A. Lesimple, M. Denis, J. Vincent, A. Larsen, O. Mamer, L. Krimbou, J. Genest, and M. Marcil. 2006. Increased sphingomyelin content impairs HDL biogenesis and maturation in human Niemann-Pick disease type B. J. Lipid Res. 47: 622-632. (Pubitemid 43345603)
101. Garner, B., A. R. Waldeck, P. K. Witting, K. A. Rye, and R. Stocker. 1998. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J. Biol. Chem. 273: 6088-6095. (Pubitemid 28144688)
102. Navab, M., J. A. Berliner, G. Subbanagounder, S. Hama, A. J. Lusis, L. W. Castellani, S. Reddy, D. Shih, W. Shi, A. D. Watson, et al. 2001. HDL and the inflammatory response induced by LDLderived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21: 481-488. (Pubitemid 32323377)
103. Marsche, G., R. Heller, G. Fauler, A. Kovacevic, A. Nuszkowski, W. Graier, W. Sattler, and E. Malle. 2004. 2-Chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler. Thromb. Vasc. Biol. 24: 2302-2306. (Pubitemid 39658033)
104. Stocker, R. 1994. Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr. Opin. Lipidol. 5: 422-433.
105. Stocker, R., and J. F. Keaney, Jr. 2004. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84: 1381-1478. (Pubitemid 39302636)
106. Subbaiah, P. V., X. C. Jiang, N. A. Belikova, B. Aizezi, Z. H. Huang, and C. A. Reardon. 2012. Regulation of plasma cholesterol esterifi cation by sphingomyelin: effect of physiological variations of plasma sphingomyelin on lecithin-cholesterol acyltransferase activity. Biochim. Biophys. Acta. 1821: 908-913.
107. Argraves, K. M., A. A. Sethi, P. J. Gazzolo, B. A. Wilkerson, A. T. Remaley, A. Tybjaerg-Hansen, B. G. Nordestgaard, S. D. Yeatts, K. S. Nicholas, J. L. Barth, et al. 2011. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 10: 70.
108. Jonas, A. 2000. Lecithin cholesterol acyltransferase. Biochim. Biophys. Acta. 1529: 245-256.
109. de Grooth, G. J., A. H. Klerkx, E. S. Stroes, A. F. Stalenhoef, J. J. Kastelein, and J. A. Kuivenhoven. 2004. A review of CETP and its relation to atherosclerosis. J. Lipid Res. 45: 1967-1974. (Pubitemid 40990890)
110. Le Goff, W., M. Guerin, and M. J. Chapman. 2004. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol. Ther. 101: 17-38. (Pubitemid 38068523)
111. Lamarche, B., S. Rashid, and G. F. Lewis. 1999. HDL metabolism in hypertriglyceridemic states: an overview. Clin. Chim. Acta. 286: 145-161. (Pubitemid 29406105)
112. Chapman, M. J., W. Le Goff, M. Guerin, and A. Kontush. 2010. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J. 31: 149-164.
113. Nobecourt, E., S. Jacqueminet, B. Hansel, S. Chantepie, A. Grimaldi, M. J. Chapman, and A. Kontush. 2005. Defective antioxidative activity of small, dense HDL particles in type 2 diabetes: Relationship to elevated oxidative stress and hyperglycemia. Diabetologia. 48: 529-538. (Pubitemid 40487300)
114. Hansel, B., P. Giral, E. Nobecourt, S. Chantepie, E. Bruckert, M. J. Chapman, and A. Kontush. 2004. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense highdensity lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 89: 4963-4971. (Pubitemid 39391435)
115. Park, K. H., D. G. Shin, J. R. Kim, J. H. Hong, and K. H. Cho. 2010. The functional and compositional properties of lipoproteins are altered in patients with metabolic syndrome with increased cholesteryl ester transfer protein activity. Int. J. Mol. Med. 25: 129-136.
116. Cabana, V. G., J. R. Lukens, K. S. Rice, T. J. Hawkins, and G. S. Getz. 1996. HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J. Lipid Res. 37: 2662-2674.
117. Sibmooh, N., P. Yamanont, S. Krudsood, W. Leowattana, G. Brittenham, S. Looareesuwan, and R. Udomsangpetch. 2004. Increased fluidity and oxidation of malarial lipoproteins: relation with severity and induction of endothelial expression of adhesion molecules. Lipids Health Dis. 3: 15.
118. Auerbach, B. J., and J. S. Parks. 1989. Lipoprotein abnormalities associated with lipopolysaccharide-induced lecithin: cholesterol acyltransferase and lipase deficiency. J. Biol. Chem. 264: 10264-10270. (Pubitemid 19159299)
119. Ettinger, W. H., L. D. Miller, J. J. Albers, T. K. Smith, and J. S. Parks. 1990. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomolgus monkeys. J. Lipid Res. 31: 1099-1107. (Pubitemid 20197812)
120. Bagdade, J. D., M. C. Ritter, and P. V. Subbaiah. 1991. Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia. J. Clin. Invest. 87: 1259-1265.
121. Frenais, R., K. Ouguerram, C. Maugeais, J. S. Marchini, P. Benlian, J. M. Bard, T. Magot, and M. Krempf. 1999. Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study. J. Lipid Res. 40: 1506-1511. (Pubitemid 29379992)
122. Guerin, M., P. J. Dolphin, C. Talussot, J. Gardette, F. Berthezene, and M. J. Chapman. 1995. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15: 1359-1368.
123. Guerin, M., T. S. Lassel, W. Le Goff, M. Farnier, and M. J. Chapman. 2000. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 20: 189-197. (Pubitemid 30048363)
124. Koizumi, J., A. Inazu, K. Yagi, I. Koizumi, Y. Uno, K. Kajinami, S. Miyamoto, P. Moulin, A. R. Tall, H. Mabuchi, et al. 1991. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. Atherosclerosis. 90: 189-196.
125. Larrede, S., C. M. Quinn, W. Jessup, E. Frisdal, M. Olivier, V. Hsieh, M-J. Kim, M. Van Eck, P. Couvert, A. Carrie, et al. 2009. Stimulation of cholesterol efflux by LXR agonists in cholesterolloaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler. Thromb. Vasc. Biol. 29: 1930-1936.
126. Nakanishi, S., R. Vikstedt, S. Soderlund, M. Lee-Rueckert, A. Hiukka, C. Ehnholm, M. Muilu, J. Metso, J. Naukkarinen, L. Palotie, et al. 2009. Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacity. J. Lipid Res. 50: 183-192.
127. Greene, D. J., J. W. Skeggs, and R. E. Morton. 2001. Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J. Biol. Chem. 276: 4804-4811.
128. Ishigami, M., S. Yamashita, N. Sakai, T. Arai, K. Hirano, H. Hiraoka, K. Kameda-Takemura, and Y. Matsuzawa. 1994. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J. Biochem. 116: 257-262. (Pubitemid 24265594)
129. Kinoshita, M., M. Fujita, S. Usui, Y. Maeda, M. Kudo, D. Hirota, T. Suda, M. Taki, M. Okazaki, and T. Teramoto. 2004. Scavenger receptor type BI potentiates reverse cholesterol transport system by removing cholesterol ester from HDL. Atherosclerosis. 173: 197-202. (Pubitemid 38469786)
130. Gelissen, I. C., K. A. Rye, A. J. Brown, R. T. Dean, and W. Jessup. 1999. Oxysterol efflux from macrophage foam cells: the essential role of acceptor phospholipid. J. Lipid Res. 40: 1636-1646. (Pubitemid 29418704)
131. Gaus, K., R. T. Dean, L. Kritharides, and W. Jessup. 2001. Inhibition of cholesterol efflux by 7-ketocholesterol: comparison between cells, plasma membrane vesicles, and liposomes as cholesterol donors. Biochemistry. 40: 13002-13014. (Pubitemid 33026647)
132. Frei, B., T. M. Forte, B. N. Ames, and C. E. Cross. 1991. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. Biochem. J. 277: 133-138.
133. Ueyama, K., M. Yokode, H. Arai, Y. Nagano, Z. X. Li, M. Cho, and T. Kita. 1998. Cholesterol efflux effect of high density lipoprotein is impaired by whole cigarette smoke extracts through lipid peroxidation. Free Radic. Biol. Med. 24: 182-190. (Pubitemid 28006451)
134. Ashraf, M. Z., N. S. Kar, X. Chen, J. Choi, R. G. Salomon, M. Febbraio, and E. A. Podrez. 2008. Specific oxidized phospholipids inhibit scavenger receptor BI-mediated selective uptake of cholesteryl esters. J. Biol. Chem. 283: 10408-10414.
135. Kontush, A., and M. J. Chapman. 2010. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr. Opin. Lipidol. 21: 312-318.
136. Kontush, A., E. C. de Faria, S. Chantepie, and M. J. Chapman. 2005. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis. 182: 277-285. (Pubitemid 41267195)
137. Zago, V., S. Sanguinetti, F. Brites, G. Berg, J. Verona, F. Basilio, R. Wikinski, and L. Schreier. 2004. Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis. 177: 203-210. (Pubitemid 39361157)
138. Kar, S., M. A. Patel, R. K. Tripathy, P. Bajaj, U. V. Suvarnakar, and A. H. Pande. 2012. Oxidized phospholipid content destabilizes the structure of reconstituted high density lipoprotein particles and changes their function. Biochim. Biophys. Acta. 1821: 1200-1210.
139. Balstad, T. R., K. B. Holven, I. O. Ottestad, K. Otterdal, B. Halvorsen, A. M. Myhre, L. Ose, and M. S. Nenseter. 2005. Altered composition of HDL3 in FH subjects causing a HDL subfraction with less atheroprotective function. Clin. Chim. Acta. 359: 171-178. (Pubitemid 41116310)
140. Persegol, L., B. Verges, M. Foissac, P. Gambert, and L. Duvillard. 2006. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia. 49: 1380-1386.
141. Sorrentino, S. A., C. Besler, L. Rohrer, M. Meyer, K. Heinrich, F. H. Bahlmann, M. Mueller, T. Horvath, C. Doerries, M. Heinemann, et al. 2010. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 121: 110-122.
142. Ekroos, K. 2012. Lipidomics perspective: from molecular lipidomics to validated clinical diagnostics. In Lipidomics: Technoogies and Applications. K. Ekroos, editor. Wiley-VCH, Weinheim, Germany. 1-19.
143. Myers, D. S., P. T. Ivanova, S. B. Milne, and H. A. Brown. 2011. Quantitative analysis of glycerophospholipids by LC-MS: acquisition, data handling, and interpretation. Biochim. Biophys. Acta. 1811: 748-757.
144. Oresic, M. 2011. Informatics and computational strategies for the study of lipids. Biochim. Biophys. Acta. 1811: 991-999.
145. Kontush, A., S. Chantepie, and M. J. Chapman. 2003. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23: 1881-1888. (Pubitemid 37254879)
146. Jaspard, B., X. Collet, R. Barbaras, J. Manent, C. Vieu, J. Parinaud, H. Chap, and B. Perret. 1996. Biochemical characterization of pre-beta 1 high-density lipoprotein from human ovarian follicular fluid: evidence for the presence of a lipid core. Biochemistry. 35: 1352-1357.